At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
NeutraSal +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NeutraSal in the Management of Xerostomia in Obstructive Sleep Apnea Syndrome (OSAS) Patients Utilizing Continuous Positive Airway Pressure (CPAP) Therapy
In Brief
A clinical study evaluating NeutraSal and Placebo Comparator for Xerostomia. Completed, enrolled 32 participants across 1 site.
Detailed Summary
To assess whether the daily use of NeutraSal will prevent or reduce dry mouth in patients undergoing CPAP therapy for OSAS and improve CPAP compliance
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsXerostomia
CountriesUnited States
CollaboratorsInvado Pharmaceuticals LLC
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedApr 2014
Primary CompletionApr 2015
Study CompletionJul 2017
TodayJul 2026
First PostedApr 8, 2014
Enrollment StartNov 1, 2013
Primary CompletionApr 10, 2015
Study CompletionJul 3, 2017
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.2 years ago
Interventions
NeutraSaldrug
NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
Placebo Comparatordrug
Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal